logo-loader
RNS
Advanced Oncotherapy PLC

Advanced Oncotherapy - Update on Financing and Current Financial Position

RNS Number : 8855Q
Advanced Oncotherapy PLC
23 October 2023
 

Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information for the purposes of Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310. With the publication of this announcement, this information is now considered to be in the public domain.

 

23 October 2023

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy", "AVO" or the "Company")

 

Update on Financing Discussions and Current Financial Position

 

On 17 July 2023 Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announced that it was exploring a recapitalisation plan aimed at providing a longer-term funding solution to support the commercial development of the LIGHT technology in a capital-intensive industry. Further to this announcement, and the subsequent announcement issued on 29 September 2023, the Company provides the following update in relation to its financing discussions and current financial position.

 

The Company has recently signed a non-binding term sheet with a third-party (the "Investor"). Under this envisaged transaction (the "Financing Transaction"), the Investor is expected to provide funding of up to c.$80 million which is intended to meet the Company's cashflow requirements through to the European certification of the LIGHT System. The treatment of first patients with LIGHT is now targeted for 2024 with certification of the LIGHT System to follow thereafter. The form and terms of this Financing Transaction will be subject to agreement on definitive documentation, satisfaction of conditions precedent and the obtaining of all requisite approvals and consents. It is anticipated the Financing Transaction will be a mixture of equity and debt financing. Discussions are progressing and further announcements on the Financing Transaction will be made at the appropriate time.

 

As previously announced the Company has been working on bridge financing to alleviate the Company's immediate financing needs. Discussions on bridge financing are ongoing and as part of these arrangements, the Company has raised £200,000 via a short-term four-month unsecured loan agreement with a new investor which carries interest at a rate of 1.25% p.m. In addition, the Company has raised £150,000 from an existing investor under its secured convertible loan note agreement. The terms are the same as those that were first announced on 1 March 2023. The Company continues to carefully manage its creditors whilst it aims to finalise the Financing Transaction.

 

As of 19 October 2023 the Company held cash of approximately £200,000. The current liabilities of the Company include £22 million owed to trade and other unsecured creditors and £39 million of financial debt. If the Financing Transaction proceeds, it is expected that a significant portion of current liabilities and financial debt will be converted into equity.

 

Whilst the board of the Company is hopeful of a satisfactory outcome, there can be no certainty that the Financing Transaction will proceed. Without access to the additional capital which is proposed to be provided by the Investor, the Company is unlikely to be able to continue to trade and would very likely become insolvent and be placed into administration.

 

Update on Formal Sale Process

 

The Company announced on 18 April 2023 the commencement of a strategic review and formal sale process under the Takeover Code (the "Formal Sale Process"). Whilst the Financing Transaction has been the Company's primary focus, the Company remains in discussions under the Formal Sale Process with strategic players in the radiotherapy sector. There can be no certainty that any offer will be made for the Company, or even proposed, or as to the terms of any proposal or offer that may be made.

 

Other implications of the Takeover Code

 

Under Rule 21 of the Takeover Code, whilst the Company remains in receipt of an approach from or in discussions with potential offerors, as defined in the Takeover Code, certain elements of the Financing Transaction may constitute frustrating action under Rule 21 of the Takeover Code. Accordingly, should this still be relevant, the Company will seek either consent from any potential offeror or will seek the approval of shareholders at a General Meeting to implement such elements of the Financing Transaction.

 

In addition, as set out in the announcement of 17 July 2023, the implementation of certain aspects of the Financing Transaction might require the granting by the Panel on Takeovers and Mergers of a waiver of certain obligations under Rule 9 of the Takeover Code and the approval of independent shareholders of the Company at a general meeting of such a waiver.

 

 

Advanced Oncotherapy Plc

www.avoplc.com

Dr. Michael Sinclair, Executive Chairman

Tel: +44 (0) 20 3617 8728

Nicolas Serandour, CEO




WH Ireland Limited (Financial adviser)

Tel: +44 (0) 20 7220 1666

Antonio Bossi / James Bavister

AVOPLC@whirelandcm.com



Allenby Capital Limited (Nomad and Joint Broker)


Nick Athanas / Piers Shimwell (Corporate Finance)

Amrit Nahal / Matt Butlin (Sales & Corporate Broking)

Tel: +44 (0) 20 3328 5656



SI Capital Ltd (Joint Broker)


Nick Emerson

Tel: +44 (0) 1483 413 500

Jon Levinson

Tel: +44 (0) 20 3871 4066



About Advanced Oncotherapy Plc www.avoplc.com

 

Advanced Oncotherapy Plc, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.

 

Advanced Oncotherapy Plc will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.

 

Advanced Oncotherapy Plc continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDMTBMTMTJTTRJ
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

6 min read